Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Interventional Cardiology
Would acute-onset thrombocytopenia and concern for active bleeding with platelet count below 50,000 prompt you to hold plavix and/or aspirin following PCI that was done 1-2 weeks ago?
Related Questions
How would you approach the timing of hemodialysis for an ESKD patient with no urgent indications who has NSTEMI with a troponin level of 10 ng/dl, has not had dialysis in 2 days, and is planned for left heart catheterization the next day?
What is your preferred duration of aggrastat therapy, and does it differ if patient presented with NSTEMI versus STEMI?
What is your stepwise approach to managing no re-flow during PCI?
What are your key takeaways regarding the difference in findings for BETA-MI DANBLOCK and REBOOT in patients post-MI with LVEF >40%?
Do you avoid high-potency P2Y12 inhibitors in favor of clopidogrel in patients with atrial fibrillation on a DOAC who undergo PCI?
Do you favor ticagrelor or prasugrel first-line for the treatment of ACS with planned PCI, provided no contraindications to either agent?
How do the results of CREST-2 influence your recommendations on screening for asymptomatic carotid stenosis?
How do you approach the decision of when to perform left heart catheterization in a patient with an NSTEMI who recently had an acute ischemic stroke?
What are your top takeaways from the updated ACS guidelines that will inform changes in clinical practice?
Would you continue SAPT beyond 12 months after left main stenting in an elderly patient on DOAC for paroxysmal atrial fibrillation?
